INSR and adrenal cortex carcinoma: Linsitinib, a dual inhibitor of the insulin-like growth factor 1 receptor (IGF1R) and insulin receptor (IR), is the only targeted drug to have entered a phase III trial for ACC patients (OSI-906) but also yielded disappointing results (12).